Skip to main content
. 2023 May 15;5(3):otad026. doi: 10.1093/crocol/otad026

Figure 5.

Figure 5.

Forest plot showing the hazard ratio of the factors associated with time to the development of anti-TNF antibodies in infliximab-treated patients. Patients with either 1 or 2 copies of the allele were considered to have carriage of the HLA-DQA1*05 variant.